Market Place
Sourcing Support
Eli Lilly`s Biologic Taltz (Ixekizumab) Receives Suppl Approvals in US
19 Aug 2024 //
FDA
Eli Lilly`s Biologic Taltz (Ixekizumab) Receives Approval in the U.S.
13 Sep 2023 //
FDA
Eli Lilly forays into dermatological space with launch of psoriasis drug
14 Mar 2023 //
ECONOMIC TIMES
Lilly`s Taltz Now Available in New, Citrate-Free Formulation
08 Aug 2022 //
PRNEWSWIRE
Eli Lilly Taltz (Ixekizumab) Receives Supplemental Approval in the U.S.
04 May 2022 //
FDA
NICE backs Lilly’s Taltz for axial spondyloarthritis
16 Jun 2021 //
PHARMATIMES
Taltz® Delivers More Cumulative Days with Completely Clear Skin for Adults
23 Apr 2021 //
PRNEWSWIRE
Sanofi teams with virtual reality biotech on oral Dupixent successor
13 Apr 2021 //
ENDPTS
Cigna dangles $500 to patients who switch to Lilly`s Taltz
06 Apr 2021 //
FIERCEPHARMA
Taltz® (ixekizumab) Approved by Health Canada for the Treatment of Pediatric
02 Apr 2021 //
YAHOO
Ixekizumab May Restores Clinical Response in Patients Hidradenitis Suppurativa
05 Nov 2020 //
FIRSTWORLDPHARMA
Lilly reports positive data from multiple psoriasis trials
30 Oct 2020 //
CLINICALTRIALSARENA
New Data at EADV 2020 Confirm Taltz® (ixekizumab) Demonstrates
29 Oct 2020 //
BIOSPACE
New Data at EADV 2020 Confirm Taltz® (ixekizumab) Long-Term Efficacy
29 Oct 2020 //
PRNEWSWIRE
Express Scripts axes Novartis` psoriasis med in favor of Lilly`s
21 Aug 2020 //
FIERCE PHARMA
Lilly bags expanded EU approval for Taltz
04 Jun 2020 //
PHARMATIMES
US FDA approves Lilly`s sBLA for Taltz to treat pediatric plaque psoriasis
31 Mar 2020 //
PHARMABIZ
Eli Lilly`s Taltz (Ixekizumab) Receives Supplemental Approval in US
31 Mar 2020 //
FDA
Chuffed on new launches, Eli Lilly unveils Street-beating 2020 sales forecast
19 Dec 2019 //
FIERCE PHARMA
Novartis` Cosentyx, Lilly`s Taltz face off in spondyloarthritis
12 Nov 2019 //
FIERCE PHARMA
Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz®
12 Nov 2019 //
PR NEWSWIRE
Lilly counts on growing markets to boost Taltz, Trulicity
25 Oct 2019 //
FIERCE PHARMA
Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients
12 Oct 2019 //
PR NEWSWIRE
Eli Lilly`s Taltz tops J&J`s Tremfya with 41% skin clearance
04 Oct 2019 //
FIERCE PHARMA
Novartis` Cosentyx chases Lilly with spondyloarthritis win
18 Sep 2019 //
FIERCE PHARMA
Eli Lilly`s Taltz (Ixekizumab) Receives Supplemental Approval in US
28 Aug 2019 //
FDA
Lilly`s Taltz wins third approval, in patients active ankylosing spondylitis
27 Aug 2019 //
ENDPTS
Leo Pharma to market AstraZeneca’s brodalumab outside Europe
16 Aug 2019 //
PMLIVE
Taltz trumps Tremfya in plaque psoriasis study
15 Aug 2019 //
PHARMA TIMES
Lilly’s Taltz meets Phase IV plaque psoriasis trial endpoints
14 Aug 2019 //
CLINICALTRIAL SARENA
Lilly bests J&J, with implications for AbbVie`s new immunology star
14 Aug 2019 //
BIOPHARMADIVE
Lilly`s Taltz bests J&J`s Tremfya in psoriasis showdown
13 Aug 2019 //
FIERCE PHARMA
AbbVie`s rising immunology star Skyrizi scores nod from England`s cost watchdog
16 Jul 2019 //
FIERCE PHARMA
Lilly Bio-Medicines chief Christi Shaw steps aside, leaving key launches behind
11 Jul 2019 //
FIERCE PHARMA
In a crowded psoriasis field, who could nab Celgene’s Otezla—and at what price?
02 Jul 2019 //
FIERCE PHARMA
Eli Lilly courts physicians with blockbuster-topping Taltz data
17 Jun 2019 //
FIERCE PHARMA
AbbVie pads Skyrizi`s blockbuster potential with positive 2-year data
11 Jun 2019 //
FIERCE PHARMA
Lilly drug scores in Phase 2 Crohn`s study
22 May 2019 //
BIOPHARMADIVE
Analysts to Lilly: Why did Trulicity and Taltz come up short?
01 May 2019 //
FIERCE PHARMA
AbbVie`s Skyrizi drug to treat psoriasis wins U.S. approval
25 Apr 2019 //
ENDPTS
Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial
18 Dec 2018 //
REUTERS
AbbVie builds case for potential psoriasis blockbuster risankizumab
13 Sep 2018 //
FIERCE BIOTECH
Lilly to Showcase New Data at the 27th EADV Congress
10 Sep 2018 //
PR NEWSWIRE
Lilly Initiates IXORA-R Head-to-Head Trial with Taltz® and Tremfya®
10 Sep 2018 //
PR NEWSWIRE
China targets Cosentyx, Shingrix and Luxturna, 45 drugs for priority approval
09 Aug 2018 //
FIERCE PHARMA
Roche stakes claim on Eli Lilly’s psoriasis med Taltz
06 Jul 2018 //
FIERCE PHARMA
Taltz®(ixekizumab): Genentech, Inc. v. Eli Lilly and Company
02 Jul 2018 //
PATENT LITIGATION
Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis
29 Jun 2018 //
ENDPTS
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz®
28 Jun 2018 //
PR NEWSWIRE
US Dermatologists Report Growth of Next-Generation Psoriasis Biologics
12 Jun 2018 //
PR NEWSWIRE
Eli Lilly to present new data from Olumiant and Taltz at annual EULAR 2018
11 Jun 2018 //
PHARMABIZ
TNF Cycling in Psoriatic Arthritis Declines for IInd Year Newly Approved Agents
30 May 2018 //
PR NEWSWIRE
